600M Chinese COVID-19 vaccines ready for market

年底前我国将有6亿支灭活疫苗获批上市

"Over the next two weeks, 600 million inactivated vaccines will be approved for marketing within the year in China", Wang Junzhi, academician and deputy leader of the Vaccine R&D Expert Group of the Scientific Research Group of the Chinese Academy of Engineering, stated at the 8th World Conference on Integrated Traditional Chinese and Western Medicine.

Wang Junzhi also expressed that as early as the beginning of the COVID outbreak, China had laid out five technical routes to develop novel coronavirus vaccines simultaneously and had organized for 12 national-leading teams to conduct joint research. 

As of December 2, there were 214 vaccines under development worldwide, of which 51 had entered clinical studies, including 14 in China. Also, 14 vaccines have entered phase III clinical trials, 6 of which are in China.

Of the six vaccines that have entered Phase III clinical trials in China, four are inactivated vaccines. In Wang Junzhi's view, for COVID-19 vaccines, regardless of which technical route is adopted, the key is to combine the pathogen's characteristics and adopt suitable processes to develop a safe and effective vaccine with strict quality control measures in place.

News written by Rachel Huang

News edited by Hazza Harding

Posted by Jessica He & Rachel Huang

Producer: Michelle Luo

Executive Producer:  Lin Weiqing